Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from CNS Pharmaceuticals (CNSP) is now available.
CNS Pharmaceuticals, Inc. has secured an exclusive license from Cortice Biosciences, Inc. for patents related to the drug compound TPI 287 across North America and Japan, with the license duration tied to commercial sales and patent expirations. The deal includes issuing shares to Cortice, milestone payments potentially in cash or stock upon achieving various development and sales targets, and royalties on sales. CNS Pharmaceuticals is also responsible for certain payments to the original intellectual property holder if required by Cortice. This strategic move aims to bolster the company’s position in the market and is funded through a private placement.
Learn more about CNSP stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue